Union Pacific's stock jumps 3.9% after earnings top estimates
Union Pacific Corp.'s stock (UNP) jumped 3.9% in premarket trade Thursday, after the railroad operator posted better-than-expected first-quarter earnings. Omaha-based Union Pacific had net income of $1.6 billion, or $2.69 a share, in the quarter, compared with $1.6 billion, or $2.67 a share, in the year-earlier period. Revenue was flat at $6.031 billion compared with $6.056 billion a year ago. The FactSet consensus was for EPS of $2.51 and revenue of $5.974 billion. CEO Jim Vena said the numbers came in a "challenging freight market and normal winter conditions." The company said its profitability outlook is gaining momentum with strong service product, improving network efficiency and solid pricing. It plans to resume share buybacks in the second quarter. The volume outlook is "muted by international intermodal business loss, lower coal demand, and soft economic conditions," the company said in a statement. The stock has fallen 5.6% in the year to date, while the S&P 500 has gained 6%.
-Ciara Linnane
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
04-25-24 0757ET
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks